SCHEMBL3541104

SCHEMBL3541104

CC(C)(C)OC(=O)N1C2CCC1CN(c1ccc3cc(Br)ccc3c1)C2

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 3/20 0.46
HSD11B1 P28845 1/20 0.45
KCNK3 O14649 1/20 0.44
KCNK9 Q9NPC2 1/20 0.44
GPR119 Q8TDV5 6/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
USP30 Q70CQ3 2/20 0.42
HDAC1 Q13547 1/20 0.40
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
PREP P48147 2/20 0.39
JAK2 O60674 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
RET P07949 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541614 0.88 JAK1 (0.47) JAK1HSD11B1KCNK3KCNK9GPR119
SCHEMBL2450967 0.88 HSD11B1 (0.50) JAK1HSD11B1KCNK3KCNK9GPR119
SCHEMBL1204097 0.88 HSD11B1 (0.50) JAK1HSD11B1KCNK3KCNK9GPR119
SCHEMBL3546251 0.86 JAK1 (0.46) JAK1HSD11B1GPR119CHRM2CHRM1
SCHEMBL16427594 0.80 CHRM2 (0.46) HSD11B1KCNK3KCNK9GPR119CHRM2
SCHEMBL23301156 0.80 GPR119 (0.47) JAK1HSD11B1GPR119CHRM2CHRM1
SCHEMBL18163889 0.80 HDAC1 (0.48) JAK1HSD11B1GPR119CHRM2CHRM1
SCHEMBL21457817 0.79 JAK1 (0.48) JAK1HSD11B1KCNK3KCNK9GPR119
SCHEMBL29577318 0.79 JAK1 (0.48) JAK1HSD11B1KCNK3KCNK9GPR119
SCHEMBL20469236 0.79 GPR119 (0.59) JAK1HSD11B1GPR119CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704991-B2 Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-04-27 US disclosed
US-20080280882-A1 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2008-11-13 US disclosed
EP-1869050-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-12-26 EP disclosed
WO-2006106090-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280882-A1 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 JAK1 3533/4885HSD11B1 1179/4885KCNK3 2351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.